Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma.

Antibodies, Monoclonal, Humanized Antineoplastic Combined Chemotherapy Protocols / therapeutic use Bevacizumab / therapeutic use Carcinoma, Hepatocellular / drug therapy Clinical Trials, Phase I as Topic Clinical Trials, Phase III as Topic Humans Inflammation / drug therapy Liver Neoplasms / drug therapy

Journal

Nature medicine
ISSN: 1546-170X
Titre abrégé: Nat Med
Pays: United States
ID NLM: 9502015

Informations de publication

Date de publication:
08 2022
Historique:
received: 27 07 2021
accepted: 11 05 2022
pubmed: 24 6 2022
medline: 23 8 2022
entrez: 23 6 2022
Statut: ppublish

Résumé

Atezolizumab (anti-programmed death-ligand 1 (PD-L1)) and bevacizumab (anti-vascular endothelial growth factor (VEGF)) combination therapy has become the new standard of care in patients with unresectable hepatocellular carcinoma. However, potential predictive biomarkers and mechanisms of response and resistance remain less well understood. We report integrated molecular analyses of tumor samples from 358 patients with hepatocellular carcinoma (HCC) enrolled in the GO30140 phase 1b or IMbrave150 phase 3 trial and treated with atezolizumab combined with bevacizumab, atezolizumab alone or sorafenib (multikinase inhibitor). Pre-existing immunity (high expression of CD274, T-effector signature and intratumoral CD8

Identifiants

DOI: 10.1038/s41591-022-01868-2 PMID: 35739268
pubmed: 35739268
doi: 10.1038/s41591-022-01868-2
pii: 10.1038/s41591-022-01868-2
doi:

Substances chimiques

Antibodies, Monoclonal, Humanized 0
Bevacizumab 2S9ZZM9Q9V
atezolizumab 52CMI0WC3Y

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1599-1611

Subventions

Organisme : NCI NIH HHS
ID : R37 CA230636
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA196521
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2022. The Author(s), under exclusive licence to Springer Nature America, Inc.

Références

Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209–249 (2021).
pubmed: 33538338 doi: 10.3322/caac.21660
Lee, M. S. et al. GO30140 Investigators. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. Lancet Oncol. 21, 808–820 (2020).
pubmed: 32502443 doi: 10.1016/S1470-2045(20)30156-X
Finn, R. S. et al. IMbrave150 Investigators. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N. Engl. J. Med. 382, 1894–1905 (2020).
pubmed: 32402160 doi: 10.1056/NEJMoa1915745
Socinski, M. A. et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N. Engl. J. Med. 378, 2288–2301 (2018).
pubmed: 29863955 doi: 10.1056/NEJMoa1716948
McDermott, D. F. et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat. Med. 24, 749–757 (2018).
pubmed: 29867230 pmcid: 6721896 doi: 10.1038/s41591-018-0053-3
Hack, S. P., Zhu, A. X. & Wang, Y. Augmenting anticancer immunity through combined targeting of angiogenic and PD-1/PD-L1 pathways: challenges and opportunities. Front. Immunol. 11, 598877 (2020).
pubmed: 33250900 pmcid: 7674951 doi: 10.3389/fimmu.2020.598877
Aran, D., Hu, Z. & Butte, A. J. xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 18, 220 (2017).
pubmed: 29141660 pmcid: 5688663 doi: 10.1186/s13059-017-1349-1
Lei, Y., Li, X., Huang, Q., Zheng, X. & Liu, M. Progress and challenges of predictive biomarkers for immune checkpoint blockade. Front. Oncol. 11, 617335 (2021).
pubmed: 33777757 pmcid: 7992906 doi: 10.3389/fonc.2021.617335
Zhang, W. et al. Fully automated 5-plex fluorescent immunohistochemistry with tyramide signal amplification and same species antibodies. Lab. Invest. 97, 873–885 (2017).
pubmed: 28504684 doi: 10.1038/labinvest.2017.37
Li, J. L. et al. DLL4-notch signaling mediates tumor resistance to anti-VEGF therapy in vivo. Cancer Res. 71, 6073–6083 (2011).
pubmed: 21803743 doi: 10.1158/0008-5472.CAN-11-1704
Zhu, A. X. et al. REACH-2 study investigators. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 20, 282–296 (2019).
pubmed: 30665869 doi: 10.1016/S1470-2045(18)30937-9
Rosenberg, J. E. et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387, 1909–1920 (2016).
pubmed: 26952546 pmcid: 5480242 doi: 10.1016/S0140-6736(16)00561-4
Rizvi, N. A. et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124–128 (2015).
pubmed: 25765070 pmcid: 4993154 doi: 10.1126/science.aaa1348
Carbone, D. P. et al. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N. Engl. J. Med. 376, 2415–2426 (2017).
pubmed: 28636851 pmcid: 6487310 doi: 10.1056/NEJMoa1613493
Kim, Y. J. et al. A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer. Lung Cancer 136, 122–128 (2019).
pubmed: 31494530 doi: 10.1016/j.lungcan.2019.08.031
de Galarreta, R. M. et al. β-catenin activation promotes immune escape and resistance to anti-PD-1 therapy in hepatocellular carcinoma. Cancer Discov. 9, 1124–1141 (2019).
doi: 10.1158/2159-8290.CD-19-0074
Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).
pubmed: 21376230 doi: 10.1016/j.cell.2011.02.013
Khan, K. A. & Kerbel, R. S. Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa. Nat. Rev. Clin. Oncol. 15, 310–324 (2018).
pubmed: 29434333 doi: 10.1038/nrclinonc.2018.9
Lee, H. G., Cho, M. Z. & Choi, J. M. Bystander CD4
pubmed: 32859954 pmcid: 8080565 doi: 10.1038/s12276-020-00486-7
Rini, B. I. et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 380, 1116–1127 (2019).
pubmed: 30779529 doi: 10.1056/NEJMoa1816714
Motzer, R. J. et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 380, 1103–1115 (2019).
pubmed: 30779531 pmcid: 6716603 doi: 10.1056/NEJMoa1816047
Makker, V. et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 20, 711–718 (2019).
pubmed: 30922731 doi: 10.1016/S1470-2045(19)30020-8
Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443–2454 (2012).
pubmed: 22658127 pmcid: 3544539 doi: 10.1056/NEJMoa1200690
Herbst, R. S. et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515, 563–567 (2014).
pubmed: 25428504 pmcid: 4836193 doi: 10.1038/nature14011
Borghaei, H. et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373, 1627 (2015).
pubmed: 26412456 pmcid: 5705936 doi: 10.1056/NEJMoa1507643
Fehrenbacher, L. et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 387, 1837–1846 (2016).
pubmed: 26970723 doi: 10.1016/S0140-6736(16)00587-0
Herbst, R. S. et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomized controlled trial. Lancet 387, 1540–1550 (2016).
pubmed: 26712084 doi: 10.1016/S0140-6736(15)01281-7
Sangro, B. et al. Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma. J. Hepatol. 73, 1460–1469 (2020).
pubmed: 32710922 pmcid: 7751218 doi: 10.1016/j.jhep.2020.07.026
Pinato, D. J. et al. Clinical implications of heterogeneity in PD-L1 immunohistochemical detection in hepatocellular carcinoma: the Blueprint-HCC study. Br. J. Cancer 120, 1033–1036 (2019).
pubmed: 31061454 pmcid: 6738063 doi: 10.1038/s41416-019-0466-x
Peng, L. S. et al. Increased tumor-infiltrating CD8(
pubmed: 22729557 doi: 10.1007/s00262-012-1277-6
Yoon, H. H. et al. Prognostic impact of FoxP3
pubmed: 22879926 pmcid: 3412852 doi: 10.1371/journal.pone.0042274
deLeeuw, R. J., Kost, S. E., Kakal, J. A. & Nelson, B. H. The prognostic value of FoxP3
pubmed: 22510350 doi: 10.1158/1078-0432.CCR-11-3216
Kalathil, S. G., Hutson, A., Barbi, J., Iyer, R. & Thanavala, Y. Augmentation of IFN-γ
pmcid: 6693832 doi: 10.1172/jci.insight.130116
Sangro, B., Sarobe, P., Hervás-Stubbs, S. & Melero, I. Advances in immunotherapy for hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol. 18, 525–543 (2021).
pubmed: 33850328 pmcid: 8042636 doi: 10.1038/s41575-021-00438-0
Ormandy, L. A. et al. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res. 65, 2457–2464 (2005).
pubmed: 15781662 doi: 10.1158/0008-5472.CAN-04-3232
Shetty, S., Lalor, P. F. & Adams, D. H. Liver sinusoidal endothelial cells—gatekeepers of hepatic immunity. Nat. Rev. Gastroenterol. Hepatol. 15, 555–567 (2018).
pubmed: 29844586 pmcid: 7096836 doi: 10.1038/s41575-018-0020-y
Dunham, R. M. et al. Hepatic stellate cells preferentially induce Foxp3
pubmed: 23359509 pmcid: 3575565 doi: 10.4049/jimmunol.1201937
Sharma, A. et al. Onco-fetal reprogramming of endothelial cells drives immunosuppressive macrophages in hepatocellular carcinoma. Cell 183, 377–394 (2020).
pubmed: 32976798 doi: 10.1016/j.cell.2020.08.040
Hellmann, M. D. et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N. Engl. J. Med. 378, 2093–2104 (2018).
pubmed: 29658845 pmcid: 7193684 doi: 10.1056/NEJMoa1801946
Hellmann, M. D. et al. Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung cancer. Cancer Cell 33, 853–861 (2018).
pubmed: 29731394 pmcid: 6750707 doi: 10.1016/j.ccell.2018.04.001
Hainsworth, J. D. et al. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, Phase IIa multiple basket study. J. Clin. Oncol. 36, 536–542 (2018).
pubmed: 29320312 doi: 10.1200/JCO.2017.75.3780
Ang, C. et al. Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma. Oncotarget 10, 4018–4025 (2019).
pubmed: 31258846 pmcid: 6592287 doi: 10.18632/oncotarget.26998
Wong, C. N. et al. Qualification of tumour mutational burden by targeted next-generation sequencing as a biomarker in hepatocellular carcinoma. Liver Int. 41, 192–203 (2021).
pubmed: 33098208 doi: 10.1111/liv.14706
Lachenmayer, A. et al. Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. Clin. Cancer Res. 18, 4997–5007 (2012).
pubmed: 22811581 pmcid: 3446854 doi: 10.1158/1078-0432.CCR-11-2322
Sohn, B. H., Park, I. Y., Shin, J. H., Yim, S. Y. & Lee, J. S. Glutamine synthetase mediates sorafenib sensitivity in β-catenin-active hepatocellular carcinoma cells. Exp. Mol. Med. 50, e421 (2018).
pubmed: 29303508 pmcid: 5992988 doi: 10.1038/emm.2017.174
Berraondo, P., Ochoa, M. C., Olivera, I. & Melero, I. Immune desertic landscapes in hepatocellular carcinoma shaped by β-catenin activation. Cancer Discov. 9, 1003–1005 (2019).
pubmed: 31371324 doi: 10.1158/2159-8290.CD-19-0696
Pinyol, R., Sia, D. & Llovet, J. M. Immune exclusion-Wnt/CTNNB1 class predicts resistance to immunotherapies in HCC. Clin. Cancer Res. 25, 2021–2023 (2019).
pubmed: 30617138 pmcid: 6445700 doi: 10.1158/1078-0432.CCR-18-3778
Harding, J. J. et al. Prospective genotyping of hepatocellular carcinoma: clinical implications of next-generation sequencing for matching patients to targeted and immune therapies. Clin. Cancer Res. 25, 2116–2126 (2019).
pubmed: 30373752 doi: 10.1158/1078-0432.CCR-18-2293
Trujillo, J. A. et al. Secondary resistance to immunotherapy associated with β-catenin pathway activation or PTEN loss in metastatic melanoma. J. Immunother. Cancer 7, 295 (2019).
pubmed: 31703593 pmcid: 6839232 doi: 10.1186/s40425-019-0780-0
Pfister, D. et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature 592, 450–456 (2021).
pubmed: 33762733 pmcid: 8046670 doi: 10.1038/s41586-021-03362-0
Terme, M. et al. VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. Cancer Res. 73, 539–549 (2013).
pubmed: 23108136 doi: 10.1158/0008-5472.CAN-12-2325
Lee, W. S., Yang, H., Chon, H. J. & Kim, C. Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity. Exp. Mol. Med. 52, 1475–1485 (2020).
pubmed: 32913278 pmcid: 8080646 doi: 10.1038/s12276-020-00500-y
Fessas, P. et al. Phenotypic characteristics of the tumour microenvironment in primary and secondary hepatocellular carcinoma. Cancers 13, 2137 (2021).
pubmed: 33946676 pmcid: 8124398 doi: 10.3390/cancers13092137
Lawrence, M., Degenhardt, J. & Gentleman, R. Package VariantTools. Bioconductor https://www.bioconductor.org/packages/devel/bioc/manuals/VariantTools/man/VariantTools.pdf (2022).
Karosiene, E., Lundegaard, C., Lund, O. & Nielsen, M. NetMHCcons: a consensus method for the major histocompatibility complex class I predictions. Immunogenetics 64, 177–186 (2012).
pubmed: 22009319 doi: 10.1007/s00251-011-0579-8
Shukla, S. A. et al. Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes. Nat. Biotechnol. 33, 1152–1158 (2015).
pubmed: 26372948 pmcid: 4747795 doi: 10.1038/nbt.3344
Canzler, S. & Hackermüller, J. multiGSEA: a GSEA-based pathway enrichment analysis for multi-omics data. BMC Bioinformatics 21, 561 (2020).
pubmed: 33287694 pmcid: 7720482 doi: 10.1186/s12859-020-03910-x

Auteurs

Andrew X Zhu (AX)

Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Jiahui International Cancer Center, Jiahui Health, Shanghai, China.

Alexander R Abbas (AR)

Department of Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA, USA.

Marina Ruiz de Galarreta (MR)

Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Liver Cancer Program, Division of Liver Diseases, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
The Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
ORCID: 0000-0001-9666-8416

Yinghui Guan (Y)

Department of Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA, USA.

Shan Lu (S)

Department of Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA, USA.

Hartmut Koeppen (H)

Department of Research Pathology, Genentech, Inc., South San Francisco, CA, USA.

Wenjun Zhang (W)

Roche Tissue Diagnostics, Tucson, AZ, USA.

Chih-Hung Hsu (CH)

Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.

Aiwu Ruth He (AR)

Division of Hematology and Oncology, Georgetown University Medical Center, Washington, DC, USA.

Baek-Yeol Ryoo (BY)

Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

Thomas Yau (T)

Department of Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.

Ahmed O Kaseb (AO)

Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Adam M Burgoyne (AM)

Division of Hematology-Oncology, UC San Diego Moores Cancer Center, La Jolla, CA, USA.

Farshid Dayyani (F)

Department of Medicine, Division of Hematology-Oncology, UC Irvine Health, Orange, CA, USA.
ORCID: 0000-0002-4970-5189

Jessica Spahn (J)

Product Development, Genentech, Inc., South San Francisco, CA, USA.

Wendy Verret (W)

Product Development, Genentech, Inc., South San Francisco, CA, USA.

Richard S Finn (RS)

The Jonsson Comprehensive Cancer Center, Geffen School of Medicine at UCLA, Los Angeles, CA, USA.

Han Chong Toh (HC)

Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.

Amaia Lujambio (A)

Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Liver Cancer Program, Division of Liver Diseases, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
The Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Graduate School of Biomedical Sciences at Icahn School of Medicine at Mount Sinai, New York, NY, USA.
ORCID: 0000-0002-2798-1481

Yulei Wang (Y)

Department of Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA, USA. wang.yulei@gene.com.
ORCID: 0000-0002-9057-9786

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Anticorps monoclonaux humanisés › Molecular correlates of clinical response and...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Association de médicaments › Protocoles de polychimiothérapie antinéoplasique › Molecular correlates of clinical response and...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Anticorps monoclonaux humanisés › Bévacizumab › Molecular correlates of clinical response and...
questionsmedicales.fr › Maladies de l'appareil digestif › Maladies du foie › Tumeurs du foie › Carcinome hépatocellulaire › Molecular correlates of clinical response and...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études cliniques comme sujet › Essais cliniques comme sujet › Essais cliniques de phase I comme sujet › Molecular correlates of clinical response and...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études cliniques comme sujet › Essais cliniques comme sujet › Essais cliniques de phase III comme sujet › Molecular correlates of clinical response and...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Molecular correlates of clinical response and...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Inflammation › Molecular correlates of clinical response and...
questionsmedicales.fr › Maladies de l'appareil digestif › Maladies du foie › Tumeurs du foie › Molecular correlates of clinical response and...